These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 1482095)
21. Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. Parnetti L; Gaiti A; Mecocci P; Cadini D; Senin U Eur J Clin Pharmacol; 1992; 42(1):89-93. PubMed ID: 1541322 [TBL] [Abstract][Full Text] [Related]
23. [Acetyl-L-carnitine (carnicetine) in the treatment of early stages of Alzheimer's disease and vascular dementia]. Gavrilova SI; Kalyn IaB; Kolykhalov IV; Roshchina IF; Selezneva ND Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(9):16-22. PubMed ID: 22027664 [TBL] [Abstract][Full Text] [Related]
24. Effects of acetyl-L-carnitine on reaction times in patients with cerebrovascular insufficiency. Arrigo A; Casale R; Buonocore M; Ciano C Int J Clin Pharmacol Res; 1990; 10(1-2):133-7. PubMed ID: 2387660 [TBL] [Abstract][Full Text] [Related]
25. Idiopathic facial paralysis: new therapeutic prospects with acetyl-L-carnitine. Mezzina C; De Grandis D; Calvani M; Marchionni A; Pomes A Int J Clin Pharmacol Res; 1992; 12(5-6):299-304. PubMed ID: 1301409 [TBL] [Abstract][Full Text] [Related]
26. The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease. Simpkins JW; Singh M; Bishop J Neurobiol Aging; 1994; 15 Suppl 2():S195-7. PubMed ID: 7700453 [No Abstract] [Full Text] [Related]
27. Pharmaco-electroencephalographic and clinical effects of the cholinergic substance--acetyl-L-carnitine--in patients with organic brain syndrome. Herrmann WM; Dietrich B; Hiersemenzel R Int J Clin Pharmacol Res; 1990; 10(1-2):81-4. PubMed ID: 2201660 [TBL] [Abstract][Full Text] [Related]
28. Studies on the degenerative and regenerative phenomena occurring after transection and repair of the sciatic nerve in rats: effects of acetyl-L-carnitine. Fernandez E; Pallini R; Gangitano C; Del Fa A; Olivieri-Sangiacomo C; Sbriccoli A; Ricoy J; Rossi GF Int J Clin Pharmacol Res; 1990; 10(1-2):85-99. PubMed ID: 2387666 [TBL] [Abstract][Full Text] [Related]
29. Up-regulation of kinesin light-chain 1 gene expression by acetyl-L-carnitine: therapeutic possibility in Alzheimer's disease. Traina G; Federighi G; Brunelli M Neurochem Int; 2008 Dec; 53(6-8):244-7. PubMed ID: 18761385 [TBL] [Abstract][Full Text] [Related]
30. Acetyl-L-carnitine for alcohol craving and relapse prevention in anhedonic alcoholics: a randomized, double-blind, placebo-controlled pilot trial. Martinotti G; Reina D; Di Nicola M; Andreoli S; Tedeschi D; Ortolani I; Pozzi G; Iannoni E; D'Iddio S; Janiri L Alcohol Alcohol; 2010; 45(5):449-55. PubMed ID: 20595193 [TBL] [Abstract][Full Text] [Related]
31. Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia. Campi N; Todeschini GP; Scarzella L Clin Ther; 1990; 12(4):306-14. PubMed ID: 2121359 [TBL] [Abstract][Full Text] [Related]
32. A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia. Lenzi A; Sgrò P; Salacone P; Paoli D; Gilio B; Lombardo F; Santulli M; Agarwal A; Gandini L Fertil Steril; 2004 Jun; 81(6):1578-84. PubMed ID: 15193480 [TBL] [Abstract][Full Text] [Related]
33. Influence of acetyl-L-carnitine infusion on haemodynamic parameters and survival of circulatory-shock patients. Gasparetto A; Corbucci GG; De Blasi RA; Antonelli M; Bagiella E; D'Iddio S; Trevisani C Int J Clin Pharmacol Res; 1991; 11(2):83-92. PubMed ID: 1879992 [TBL] [Abstract][Full Text] [Related]
34. Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain. Bonavita E Int J Clin Pharmacol Ther Toxicol; 1986 Sep; 24(9):511-6. PubMed ID: 3781687 [TBL] [Abstract][Full Text] [Related]
36. [Physiological functions of carnitine and carnitine transporters in the central nervous system]. Inazu M; Matsumiya T Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Jun; 28(3):113-20. PubMed ID: 18646596 [TBL] [Abstract][Full Text] [Related]
37. The effect of acetyl-L-carnitine administration on persons with Down syndrome. Pueschel SM Res Dev Disabil; 2006; 27(6):599-604. PubMed ID: 16621446 [TBL] [Abstract][Full Text] [Related]
38. L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. Bersani G; Meco G; Denaro A; Liberati D; Colletti C; Nicolai R; Bersani FS; Koverech A Eur Neuropsychopharmacol; 2013 Oct; 23(10):1219-25. PubMed ID: 23428336 [TBL] [Abstract][Full Text] [Related]
39. [Effect of the chronic treatment with L-acetylcarnitine in Down's syndrome]. De Falco FA; D'Angelo E; Grimaldi G; Scafuro F; Sachez F; Caruso G Clin Ter; 1994 Feb; 144(2):123-7. PubMed ID: 8181206 [TBL] [Abstract][Full Text] [Related]
40. Clinical pharmacodynamics of acetyl-L-carnitine in patients with Parkinson's disease. Puca FM; Genco S; Specchio LM; Brancasi B; D'Ursi R; Prudenzano A; Miccoli A; Scarcia R; Martino R; Savarese M Int J Clin Pharmacol Res; 1990; 10(1-2):139-43. PubMed ID: 2387661 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]